MX2021009033A - Sales de sulcardina. - Google Patents

Sales de sulcardina.

Info

Publication number
MX2021009033A
MX2021009033A MX2021009033A MX2021009033A MX2021009033A MX 2021009033 A MX2021009033 A MX 2021009033A MX 2021009033 A MX2021009033 A MX 2021009033A MX 2021009033 A MX2021009033 A MX 2021009033A MX 2021009033 A MX2021009033 A MX 2021009033A
Authority
MX
Mexico
Prior art keywords
salts
sulcardine
sulcardine salts
administration
methods
Prior art date
Application number
MX2021009033A
Other languages
English (en)
Spanish (es)
Inventor
Robert Goodenow
Mireille Gillings
Suzanne J Romano
Gary T Elliott
Hayley Ann Reece
Joseph Edward Gordon Benson
Sarah Collins
Curtis Tyree
Original Assignee
Huya Bioscience Int Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huya Bioscience Int Llc filed Critical Huya Bioscience Int Llc
Publication of MX2021009033A publication Critical patent/MX2021009033A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42—Separation; Purification; Stabilisation; Use of additives
    • C07C303/44—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Inorganic Chemistry (AREA)
MX2021009033A 2019-01-29 2020-01-28 Sales de sulcardina. MX2021009033A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962798467P 2019-01-29 2019-01-29
US202062959687P 2020-01-10 2020-01-10
PCT/US2020/015370 WO2020159959A1 (en) 2019-01-29 2020-01-28 Sulcardine salts

Publications (1)

Publication Number Publication Date
MX2021009033A true MX2021009033A (es) 2021-10-13

Family

ID=69724142

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021009033A MX2021009033A (es) 2019-01-29 2020-01-28 Sales de sulcardina.
MX2023014776A MX2023014776A (es) 2019-01-29 2021-07-27 Sales de sulcardina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023014776A MX2023014776A (es) 2019-01-29 2021-07-27 Sales de sulcardina.

Country Status (16)

Country Link
US (4) US11426382B2 (cg-RX-API-DMAC10.html)
EP (1) EP3917921A1 (cg-RX-API-DMAC10.html)
JP (3) JP2022518906A (cg-RX-API-DMAC10.html)
KR (2) KR102405199B1 (cg-RX-API-DMAC10.html)
CN (2) CN112638903B (cg-RX-API-DMAC10.html)
AU (1) AU2020216925B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021014640A8 (cg-RX-API-DMAC10.html)
CA (1) CA3128152A1 (cg-RX-API-DMAC10.html)
CL (1) CL2021001968A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021011042A2 (cg-RX-API-DMAC10.html)
IL (1) IL285184B2 (cg-RX-API-DMAC10.html)
MX (2) MX2021009033A (cg-RX-API-DMAC10.html)
PH (1) PH12021551818A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202108160YA (cg-RX-API-DMAC10.html)
WO (1) WO2020159959A1 (cg-RX-API-DMAC10.html)
ZA (2) ZA202105344B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020123824A1 (en) 2018-12-13 2020-06-18 Huya Bioscience International, Llc Sulcardine administration for treatment of acute atrial fibrillation
KR102405199B1 (ko) * 2019-01-29 2022-06-02 후야 바이오사이언스 인터내셔널 엘엘씨 설카딘 염
US11813245B2 (en) * 2020-06-12 2023-11-14 Huyabio International, Llc Sulcardine administration for treatment of acute atrial fibrillation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1172908C (zh) * 1999-12-10 2004-10-27 中国科学院上海药物研究所 N-取代苄基或苯基芳香磺酰胺化合物及其用途
CN1299813C (zh) 2004-12-28 2007-02-14 华南理工大学 自动撕膜落料及多样性搅拌的机构和控制装置
CN1939298A (zh) * 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
US8541464B2 (en) 2009-11-17 2013-09-24 HUYA Biosciences International LLC Treatment of atrial fibrillation
WO2011062903A2 (en) * 2009-11-17 2011-05-26 Elliott Gary T Slow infusion of sulcardine and its salts
MA41599A (fr) * 2015-02-26 2018-01-02 Array Biopharma Inc Formes cristallines d'un composé pyrrolopyridine
EP3302442B1 (en) 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
AU2017261372B2 (en) 2016-05-05 2019-02-14 Triastek, Inc. Controlled release dosage form
AU2018212273B2 (en) 2017-01-26 2023-12-21 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
US10370381B2 (en) * 2017-02-24 2019-08-06 Gilead Sciences, Inc. Inhibitors of bruton'S tyrosine kinase
WO2020123824A1 (en) 2018-12-13 2020-06-18 Huya Bioscience International, Llc Sulcardine administration for treatment of acute atrial fibrillation
KR102405199B1 (ko) * 2019-01-29 2022-06-02 후야 바이오사이언스 인터내셔널 엘엘씨 설카딘 염

Also Published As

Publication number Publication date
AU2020216925B2 (en) 2022-09-15
ZA202107474B (en) 2022-06-29
US20250144072A9 (en) 2025-05-08
KR102405199B1 (ko) 2022-06-02
CN115385871A (zh) 2022-11-25
US20200316024A1 (en) 2020-10-08
CL2021001968A1 (es) 2022-01-28
JP2025165933A (ja) 2025-11-05
IL285184A (en) 2021-09-30
IL285184B2 (en) 2023-12-01
CO2021011042A2 (es) 2022-01-17
US20260232630A1 (en) 2026-08-13
MX2023014776A (es) 2024-01-15
JP2022518906A (ja) 2022-03-17
US20220356319A1 (en) 2022-11-10
CN112638903B (zh) 2022-08-26
CA3128152A1 (en) 2020-08-06
EP3917921A1 (en) 2021-12-08
KR102697726B1 (ko) 2024-08-21
BR112021014640A8 (pt) 2022-12-20
PH12021551818A1 (en) 2022-03-28
AU2020216925A1 (en) 2021-09-02
US11426382B2 (en) 2022-08-30
US12678422B2 (en) 2026-07-14
KR20210130157A (ko) 2021-10-29
US11020374B2 (en) 2021-06-01
CN112638903A (zh) 2021-04-09
KR20220079688A (ko) 2022-06-13
BR112021014640A2 (pt) 2021-09-21
JP2024039020A (ja) 2024-03-21
IL285184B1 (en) 2023-08-01
ZA202105344B (en) 2023-01-25
US20210038568A1 (en) 2021-02-11
WO2020159959A1 (en) 2020-08-06
SG11202108160YA (en) 2021-08-30

Similar Documents

Publication Publication Date Title
CR20230310A (es) Inhibidores de prmt5
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
CU20210065A7 (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibitoria en cdk2
MY209609A (en) Immunomodulators, compositions and methods thereof
MX389597B (es) Inhibidores de cdk2/4/6 de piridopirimidinona.
MX2025010928A (es) Compuestos de alquinil quinazolina
PH12018500212A1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
EP4360707A3 (en) Compositions for treating spinal muscular atrophy
PH12021500034A1 (en) Compounds useful in hiv therapy
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
WO2016118951A3 (en) Heterocyclic itk inhibitors for treating inflammation and cancer
MX389965B (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos
TN2016000529A1 (en) Substituted dihydroisoquinolinone compounds
MX2023014776A (es) Sales de sulcardina.
MX2021009806A (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
MX2020004981A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
MY178445A (en) Novel antibody binding to tfpi and composition comprising the same
PH12018501285A1 (en) Alkyl dihydroquinoline sulfonamide compounds
PH12021552133A1 (en) Aromatic derivatives, preparation methods, and medical uses thereof
EA201691962A1 (ru) Амидозамещенные азольные соединения в качестве ингибиторов tnks1 и/или tnks2
MX378164B (es) Amidas aromaticas de acido carboxilico.
MX2020001199A (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas.